Hikma Pharmaceuticals PLC (LON:HIK) Insider Mazen Darwazah Purchases 200,000 Shares

Hikma Pharmaceuticals PLC (LON:HIK) insider Mazen Darwazah bought 200,000 shares of the company’s stock in a transaction that occurred on Thursday, August 7th. The shares were purchased at an average cost of GBX 1,756 ($23.62) per share, for a total transaction of £3,512,000 ($4,723,604.57).

Hikma Pharmaceuticals Trading Down 1.1%

LON HIK opened at GBX 1,729.97 ($23.27) on Friday. Hikma Pharmaceuticals PLC has a twelve month low of GBX 1,690 ($22.73) and a twelve month high of GBX 2,360 ($31.74). The company has a debt-to-equity ratio of 55.82, a quick ratio of 1.27 and a current ratio of 1.66. The stock has a market cap of £4.80 billion, a price-to-earnings ratio of 16.98, a PEG ratio of 2.38 and a beta of 0.41. The firm’s 50 day moving average price is GBX 2,010.20 and its two-hundred day moving average price is GBX 2,050.20.

Analyst Ratings Changes

Several research analysts have issued reports on HIK shares. JPMorgan Chase & Co. decreased their price target on shares of Hikma Pharmaceuticals from GBX 2,600 ($34.97) to GBX 2,500 ($33.62) and set an “overweight” rating on the stock in a research report on Friday. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,600 ($34.97) price target on shares of Hikma Pharmaceuticals in a research report on Thursday.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.